A trial of Imatinib (Glivec) for soft tissue sarcoma of the skin (EORTC 62027)

Cancer type:

Soft tissue sarcoma




Phase 2

This trial looked at imatinib (Glivec) for two rare types of soft tissue sarcoma of the skin. These are called dermatofibrosarcoma protuberans (DFSP) and giant cell fibroblastoma (GCF).

Doctors usually remove DFSP and GCF with surgery. But sometimes they are not able to remove the whole area of sarcoma, or the cancer may start to grow again after the operation. These sarcomas can sometimes spread to another part of the body, although this is rare. If cancer continues to grow or spreads to another area of the body, it is often more difficult to treat.

Imatinib (Glivec) is a type of treatment called a tyrosine kinase inhibitor (TKI). This means it blocks enzymes called tyrosine kinases Open a glossary item, which are part of the system that tells the cell to grow. If TKs could be stopped from working in cancer cells, then the cells should stop growing and dividing.

The research team hoped that imatinib would work on cells that contain a specific protein. This protein, called COL1A1/PGDF, is found in dermatofibrosarcoma protuberans and giant cell fibroblastoma cells.

Imatinib has been shown to work well for some other cancers, such as gastrointestinal stromal sarcoma (GIST) and chronic myeloid leukaemia (CML). But the researchers were not sure how well it would work for these rare types of sarcoma of the skin.

The aims of this trial were to find out

  • How well imatinib worked for DFSP and GCF
  • More about the side effects

Summary of results

When the trial closed, it had recruited only people with dermatofibrosarcoma protuberans (DFSP). The trial team found that DFPS responded well to imatinib.

This trial recruited 16 people. Everyone had imatinib.

After 14 weeks treatment, the researchers were able to assess how the cancer had responded in 14 of the 16 people. Of these people their cancer had

  • Shrunk in 5
  • Stayed the same in 6
  • Continued to grow in 3

The average amount of time it took for the DFSP to start growing again was over 1 and a half years.

The most common side effects were

The trial team concluded that imatinib worked well for people with DFSP.

We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (peer reviewed Open a glossary item) and published in a medical journal. The figures we quote above were provided by the trial team. We have not analysed the data ourselves.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Dr Michael Leahy

Supported by

European Organisation for Research and Treatment of Cancer (EORTC)
Experimental Cancer Medicine Centre (ECMC)

If you have questions about the trial please contact our cancer information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle - 732

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Cara took part in a clinical trial

A picture of Cara

"I am glad that taking part in a trial might help others on their own cancer journey.”

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think